Home » Stocks » Axsome Therapeutics

Axsome Therapeutics, Inc. (AXSM)

Stock Price: $81.43 USD 3.36 (4.30%)
Updated Aug 10, 2020 11:10 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 3.02B
Revenue (ttm) n/a
Net Income (ttm) -90.19M
Shares Out 37.08M
EPS (ttm) -2.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $81.43
Previous Close $78.07
Change ($) 3.36
Change (%) 4.30%
Day's Open 79.03
Day's Range 76.35 - 81.50
Day's Volume 202,584
52-Week Range 13.64 - 109.94

More Stats

Market Cap 3.02B
Enterprise Value 2.84B
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 37.08M
Float 27.18M
EPS (basic) -2.57
EPS (diluted) -2.58
FCF / Share -1.62
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.86M
Short Ratio 6.32
Short % of Float 13.41%
Beta 2.96
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 18.53
Revenue n/a
Operating Income -89.32M
Net Income -90.19M
Free Cash Flow -60.17M
Net Cash 177.20M
Net Cash / Share 4.78
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -40.84%
ROE -103.95%
ROIC -344,347.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 9
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$162.22*
(99.21% upside)
Low
115
Current: $81.43
High
210
Target: 162.22
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue-------
Operating Income-67.25-32.85-27.16-27.54-9.20-5.67-1.84
Net Income-68.35-30.97-28.94-27.20-12.21-6.00-2.17
Shares Outstanding34.0226.8822.7619.1511.959.107.69
Earnings Per Share-2.01-1.15-1.27-1.42-1.02-0.66-0.28
Operating Cash Flow-46.38-30.05-26.47-21.28-7.44-4.60-1.63
Capital Expenditures-0.02-0.03-0.01-0.10-0.02--
Free Cash Flow-46.39-30.09-26.48-21.39-7.46-4.60-1.63
Cash & Equivalents22013.9734.0236.6248.042.622.09
Total Debt19.936.919.939.74-4.483.83
Net Cash / Debt2007.0624.0926.8848.04-1.87-1.74
Assets22115.3835.5638.2149.082.792.10
Liabilities41.8314.4418.8416.642.635.994.13
Book Value1790.9416.7221.5746.44-3.20-2.03
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Axsome Therapeutics, Inc.
Country United States
Employees 45
CEO Herriott Tabuteau

Stock Information

Ticker Symbol AXSM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AXSM
IPO Date November 19, 2015

Description

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.